Project Grant R41AG079748
Award Date
9/25/24
Completion Date
8/31/25
Dollars Obligated
$949K
Federal Agency
National Institute on Aging
Awardee
Somatoceutics LLC (JENWTGNEHTJ5)
Federal Grant Program
93.866
Assistance Type
Project Grant
Place of Performance
Charleston, SC 29403, USA
Similar Awards
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $295,000 to Florida International University to develop a novel biotherapeutic nanogel system for the treatment of Alzheimer's disease. The key objectives are to enhance the nanogel's ability to cross the blood-brain barrier and improve its efficacy in ameliorating oxidative stress, neuroinflammation, amyloid and tau pathology, and cognitive decline associated with Alzheimer's disease. The...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $1,041,646 to Cenna Biosciences Inc. to support the early clinical development of their modified P8 peptide drug candidate for the treatment of Alzheimer's disease. The key products and services to be delivered under this grant include: 1) Chemistry, Manufacturing, and Controls (CMC) activities to support clinical development of the drug product, 2) a pre-IND meeting with the FDA and...
The National Institute on Aging, under the Aging Research Federal Grant Program (CFDA 93.866), awarded a $504,732 Project Grant to Aphios Corp on September 25, 2024 for the "Development of a Novel Alzheimer's Disease Therapeutic". The project aims to develop targeted nanoparticles containing an anti-CCR5 drug to address brain inflammation associated with Alzheimer's disease. In Phase I, the grant will fund the nanoencapsulation and characterization of the anti-CCR5 drug, as well as...
This Project Grant award of $500,000 from the National Institute on Aging (CFDA 93.866 Aging Research) supports the development of a multi-target peptide drug called ALZ100 by Alzarrok Bio LLC for the treatment of Alzheimer's disease (AD). The project aims to demonstrate the in vivo efficacy of ALZ100 in inhibiting neuroinflammation and neurodegeneration in an AD mouse model. The key products and services to be delivered include: Infusing wild-type and AD transgenic mouse brains with varying...
This $506,451 Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) aims to develop an effective targeted delivery system for small interfering RNA (siRNA) therapeutics to mitigate neuroinflammatory diseases such as Alzheimer's disease. The key products or services to be delivered under this award include: Optimizing the delivery of siRNA against the inflammatory regulator NF-kB (SINFKB) using folic acid-functionalized exosomal vectors, both in vitro and in...
This federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $499,441 to Acepre, LLC to develop a novel brain-targeted delivery system for N-acetylcysteine (TN-NAC) as a potential treatment for Alzheimer's disease (AD). The project aims to evaluate the toxicity, pharmacokinetics, and therapeutic efficacy of TN-NAC in mouse models of AD. The successful completion of the proposed studies will serve as a milestone for further development of TN-NAC as...
The National Institute on Aging (NIA) awarded Neucyte Inc., a minority-owned small business, a $500,000 Project Grant under the Aging Research program (CFDA 93.866) to develop a nanoluciferase-based microphysiological systems platform for high-throughput screening of Alzheimer's disease (AD) and AD-related dementia (ADRD) therapeutics. The platform will utilize induced pluripotent stem cell-derived "mini-brain" assembloids to create scalable, reproducible 3D brain models that better...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $499,998 to Encue Inc., a small disadvantaged business, to develop novel small molecule modulators of synaptic plasticity for the treatment of Alzheimer's disease (AD)-induced cognitive decline. The project aims to further develop the lead molecule JB2, which has shown potential to reverse cognitive deficits in a mouse model of Alzheimer's by restoring normal expression and function of...
This federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) to Transchromix LLC in Chapel Hill, NC provides $994,436 to develop novel brain-penetrant drugs for treating Alzheimer's disease (AD). The researchers aim to further investigate a noncanonical, translation regulatory function of the histone methyltransferase G9A in AD pathogenesis, building on their prior discovery that G9A inhibition by the drug MS1262 can reverse AD-associated protein...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $509,038 to Ceiba Bio Inc. to develop a blood-based exercise mimetic as a potential treatment for Alzheimer's disease and related dementias. The key objectives are to: 1) identify 3 lead recombinant human GPLD1 molecules, 2) conduct in vivo pharmacokinetic profiling of the 3 lead GPLD1 molecules in aged mice, and 3) test 1 primary and 1 alternate lead GPLD1 molecule for disease modification in a...